Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Email

Publications for Follow-up Study of Women Evaluated and Treated for Infertility

Brinton LA, Lamb EJ, Moghissi KS, Scoccia B, Althuis MD, Mabie JE, Westhoff CL. Ovarian cancer risk after the use of ovulation-stimulating drugs. Obstet Gynecol 2004;103:1194-203.

Brinton LA, Lamb EJ, Moghissi KS, Scoccia B, Althuis MD, Mabie JE, Westhoff CL. Ovarian cancer risk associated with varying causes of infertility. Fertil Steril 2004;82:405-414.

Brinton LA, Scoccia B, Moghissi KS, Westhoff CL, Althuis MD, Mabie JE, Lamb EJ. Breast cancer risk associated with ovulation-stimulating drugsHum Reprod 2004;19:2005-2013 .

Brinton LA, Moghissi KS, Scoccia B, Westhoff CL, Lamb EJ.  Ovulation induction and cancer risk (Review).  Fertil Steril 2005;83:261-274.

Althuis MD, Moghissi KS, Westhoff CL, Scoccia B, Lamb EJ, Lubin JH, Brinton LA. Uterine cancer after use of clomiphene citrate to induce ovulation. Am J Epidemiol 2005;161:607-615.

Brinton LA, Westhoff CL, Scoccia B, Lamb EJ, Althuis MD, Mabie JE, Moghissi KS. Causes of infertility as predictors of subsequent cancer risk. Epidemiology 2005;16:500-507.

Althuis MD, Scoccia B, Lamb EJ, Moghissi KS, Westhoff CL, Mabie JE, Brinton LA. Melanoma, thyroid, cervical and colon cancer risk after use of fertility drugs. Am J Obstet Gynecol 2005;193:668-674.

Brinton LA, Moghissi KS, Westhoff CL, Lamb EJ, Scoccia B. Cancer risk among infertile women with androgen excess or menstrual disorders (including polycystic ovary syndrome). Fertil Steril 2010;94:1787-93. PMCID: PMC2888728.

Brinton LA, Westhoff CL, Scoccia B, Lamb EJ, Trabert B, Niwa S, Moghissi KS. Fertility drugs and endometrial cancer risk: results from an extended follow-up of a large infertility cohort. Hum Reprod 2013;28:2813-2821. PMCID: PMC3777572.

Trabert B, Lamb EJ, Scoccia B, Moghissi KS, Westhoff CL, Niwa S, Brinton LA.  Ovulation-inducing drugs and ovarian cancer risk: results from an extended follow-up of a large United States infertility cohort. Fertil Steril 2013;100:1660-1666. PMCID: PMC3873340.

Brinton LA, Scoccia B, Moghissi KS, Westhoff CL, Niwa S, Trabert B, Lamb EJ. Long-term relationship of ovulation-stimulating drugs to breast cancer risk. Cancer Epidemiol Biomarkers Prev 2014;23:584-593. PMCID: PMC3979528.

Reigstad MM, Larsen IK, Myklebust TA, Robsahm TE, Oldereid NB, Omland AK, Vangen S, Brinton LA, Storeng R. Risk of breast cancer following fertility treatment-A registry based cohort study of parous women in Norway. Int J Cancer 2014 Jul 9; doi: 10.1002/ijc.29069. [Epub ahead of print]

Email